- Home
- PAM vs AKRO Comparison
PAM vs AKRO Comparison
Compare PAM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAM
- AKRO
- Stock Information
- Founded
- PAM 1945
- AKRO 2017
- Country
- PAM Argentina
- AKRO United States
- Employees
- PAM N/A
- AKRO N/A
- Industry
- PAM Electric Utilities: Central
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PAM Utilities
- AKRO Health Care
- Exchange
- PAM Nasdaq
- AKRO Nasdaq
- Market Cap
- PAM 4.4B
- AKRO 3.9B
- IPO Year
- PAM N/A
- AKRO 2019
- Fundamental
- Price
- PAM $70.70
- AKRO $54.20
- Analyst Decision
- PAM Buy
- AKRO Strong Buy
- Analyst Count
- PAM 3
- AKRO 6
- Target Price
- PAM $85.83
- AKRO $82.50
- AVG Volume (30 Days)
- PAM 158.5K
- AKRO 1.8M
- Earning Date
- PAM 08-06-2025
- AKRO 08-08-2025
- Dividend Yield
- PAM N/A
- AKRO N/A
- EPS Growth
- PAM 32.60
- AKRO N/A
- EPS
- PAM 0.41
- AKRO N/A
- Revenue
- PAM $1,970,436,590.00
- AKRO N/A
- Revenue This Year
- PAM $23.47
- AKRO N/A
- Revenue Next Year
- PAM $22.99
- AKRO N/A
- P/E Ratio
- PAM $7.19
- AKRO N/A
- Revenue Growth
- PAM 21.62
- AKRO N/A
- 52 Week Low
- PAM $38.58
- AKRO $21.02
- 52 Week High
- PAM $97.55
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- PAM 37.65
- AKRO 62.96
- Support Level
- PAM $72.51
- AKRO $53.61
- Resistance Level
- PAM $74.92
- AKRO $56.49
- Average True Range (ATR)
- PAM 2.79
- AKRO 2.40
- MACD
- PAM -0.52
- AKRO -0.08
- Stochastic Oscillator
- PAM 1.54
- AKRO 65.93
About PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.